Atrys Health, S.A. (ATRY.MC)
EUR 2.85
(0.35%)
EUR 2.85
(0.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 31.91 Million EUR | -13.55% |
| 2022 | 16.62 Million EUR | 358.3% |
| 2021 | 5.87 Million EUR | 75.69% |
| 2020 | 4.8 Million EUR | 56.71% |
| 2019 | 3.17 Million EUR | 50.86% |
| 2018 | 1.96 Million EUR | 18.81% |
| 2017 | 1.66 Million EUR | 48.46% |
| 2016 | 1.73 Million EUR | -38.08% |
| 2015 | 1.88 Million EUR | 181.55% |
| 2014 | 661.34 Thousand EUR | 237.46% |
| 2013 | 186.71 Thousand EUR | -62.77% |
| 2012 | 526.34 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 8.58 Million EUR | -18.26% |
| 2024 Q2 | 3.56 Million EUR | -58.51% |
| 2023 Q1 | 4.79 Million EUR | -47.86% |
| 2023 Q4 | 13.14 Million EUR | 516.51% |
| 2023 FY | - EUR | -13.55% |
| 2023 Q3 | 2.13 Million EUR | -87.77% |
| 2023 Q2 | 17.43 Million EUR | 263.5% |
| 2022 Q2 | 13.42 Million EUR | 128.83% |
| 2022 FY | - EUR | 358.3% |
| 2022 Q3 | 9.43 Million EUR | -29.68% |
| 2022 Q1 | 5.86 Million EUR | 130.63% |
| 2022 Q4 | 9.19 Million EUR | -2.55% |
| 2021 Q4 | -19.14 Million EUR | -2768.36% |
| 2021 Q2 | 7.34 Million EUR | 112.26% |
| 2021 Q3 | 717.5 Thousand EUR | -90.23% |
| 2021 FY | - EUR | 75.69% |
| 2021 Q1 | 3.45 Million EUR | 28.33% |
| 2020 FY | - EUR | 56.71% |
| 2020 Q2 | 646 Thousand EUR | -0.0% |
| 2020 Q1 | 646 Thousand EUR | -60.06% |
| 2020 Q3 | 2.69 Million EUR | 317.26% |
| 2020 Q4 | 2.69 Million EUR | 0.0% |
| 2019 Q4 | 1.61 Million EUR | 41.26% |
| 2019 Q2 | 1.21 Million EUR | 99.36% |
| 2019 Q3 | 1.14 Million EUR | -6.08% |
| 2019 Q1 | 611.47 Thousand EUR | -58.93% |
| 2019 FY | - EUR | 50.86% |
| 2018 Q1 | 453.38 Thousand EUR | 35.36% |
| 2018 FY | - EUR | 18.81% |
| 2018 Q4 | 1.48 Million EUR | 277.41% |
| 2018 Q3 | 394.52 Thousand EUR | -56.54% |
| 2018 Q2 | 907.81 Thousand EUR | 100.23% |
| 2017 Q4 | 334.95 Thousand EUR | 0.0% |
| 2017 FY | - EUR | 48.46% |
| 2017 Q2 | 351.86 Thousand EUR | -0.0% |
| 2017 Q1 | 351.86 Thousand EUR | 3112.77% |
| 2017 Q3 | 334.95 Thousand EUR | -4.8% |
| 2016 Q1 | -4336.00 EUR | 0.0% |
| 2016 Q2 | -4335.00 EUR | 0.02% |
| 2016 FY | - EUR | -38.08% |
| 2016 Q4 | -11.67 Thousand EUR | 91.69% |
| 2016 Q3 | -140.46 Thousand EUR | -3140.25% |
| 2015 FY | - EUR | 181.55% |
| 2014 FY | - EUR | 237.46% |
| 2013 FY | - EUR | -62.77% |
| 2012 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biotechnologies Assets SA | 5.09 Million EUR | -525.894% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 819.861% |
| Pharma Mar, S.A. | 4.54 Million EUR | -601.561% |
| Laboratorios Farmaceuticos Rovi, S.A. | 245.81 Million EUR | 87.017% |